Trial Profile
A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2008
Price :
$35
*
At a glance
- Drugs Mitoxantrone (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 27 Dec 2007 Status changed from in progress to discontinued as reported on clinicaltrials.gov website.
- 20 Nov 2005 New trial record.